Your browser doesn't support javascript.
loading
EPHA5 mediates trastuzumab resistance in HER2-positive breast cancers through regulating cancer stem cell-like properties.
Li, Yongfei; Chu, Jiahui; Feng, Wanting; Yang, Mengzhu; Zhang, Yanhong; Zhang, Yanqiu; Qin, Ye; Xu, Juan; Li, Jun; Vasilatos, Shauna N; Fu, Ziyi; Huang, Yi; Yin, Yongmei.
Affiliation
  • Li Y; Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
  • Chu J; Department of Pharmacology and Chemical Biology, University of Pittsburgh Medical Center (UPMC) Hillman Cancer Center, University of Pittsburgh, Pittsburgh, Pennsylvania, USA; and.
  • Feng W; Department of Breast Diseases, Jiangsu Province Hospital of Traditional Chinese Medicine (TMC)/Affiliated Hospital of Nanjing University of TCM, Nanjing, China.
  • Yang M; Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
  • Zhang Y; Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
  • Zhang Y; Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
  • Qin Y; Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
  • Xu J; Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
  • Li J; Department of Pharmacology and Chemical Biology, University of Pittsburgh Medical Center (UPMC) Hillman Cancer Center, University of Pittsburgh, Pittsburgh, Pennsylvania, USA; and.
  • Vasilatos SN; Nanjing Maternal and Child Health Medical Institute, Affiliated Obstetrics and Gynecology Hospital, Nanjing Medical University, Nanjing, China.
  • Fu Z; Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
  • Huang Y; Department of Pharmacology and Chemical Biology, University of Pittsburgh Medical Center (UPMC) Hillman Cancer Center, University of Pittsburgh, Pittsburgh, Pennsylvania, USA; and.
  • Yin Y; Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
FASEB J ; 33(4): 4851-4865, 2019 04.
Article de En | MEDLINE | ID: mdl-30620624
Sujet(s)
Mots clés
Texte intégral
Ajouter à My VHL
Imprimer
XML
PubMed Links
Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Tumeurs du sein / Récepteur EphA5 / Trastuzumab Type d'étude: Prognostic_studies Limites: Animals / Female / Humans / Middle aged Langue: En Journal: FASEB J Sujet du journal: BIOLOGIA / FISIOLOGIA Année: 2019 Type de document: Article Pays d'affiliation: Chine Pays de publication: États-Unis d'Amérique
Texte intégral
Ajouter à My VHL
Imprimer
XML
PubMed Links
Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Tumeurs du sein / Récepteur EphA5 / Trastuzumab Type d'étude: Prognostic_studies Limites: Animals / Female / Humans / Middle aged Langue: En Journal: FASEB J Sujet du journal: BIOLOGIA / FISIOLOGIA Année: 2019 Type de document: Article Pays d'affiliation: Chine Pays de publication: États-Unis d'Amérique